Skip to main content
. 2014 Sep 25;4:138. doi: 10.3389/fcimb.2014.00138

Figure 1.

Figure 1

Fungal and mammal GSLs biosynthetic pathways and potential targets for new antifungal therapies. The scheme displays the biosynthetic pathways of fungal GIPCs (left), fungal GlcCer (center), and mammalian GSLs (right). The red arrows indicates the biosynthetic step where the inhibition by AbA and P4/analogs occurs, the red dashed boxes in the glycosphingolipid biosynthetic pathway indicate potential targets for the development of new antifungal therapies. LCB, long chain base; FA, fatty acid; IPC, inositol phosphorylceramide; MIPC, mannosylinositol phosphorylceramide; GIPC, glycosylinositol phosphorylceramide; AbA, Aureobasidin A; P4, D-threo-1-phenyl-2-palmitoyl-3-pyrrolidinopropanol.